Homoharringtonine

Name	Value
Weight	545.629 g/mol
Zinc ID	ZINC43450324
Smiles	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@@H]13)OCO4
Molecular formula	C29H39NO9
Mode of inhibition	N/A
CAS	26833-87-4

Clinical Trials

Show entries

Search:

Study title	Status	Conditions	Link
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)	Withdrawn	Myelodysplastic Syndromes	NCT02835794
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy	Not yet recruiting	Leukemia, Myeloid, Acute	NCT04824924
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase	Active, not recruiting	Chronic Myeloid Leukemia, Chronic Phase	NCT04126681
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC	Recruiting	Myelodysplastic Syndromes,Acute Myeloid Leukemia	NCT03978364
A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated	Recruiting	Acute Myeloid Leukemia (AML)	NCT04716114
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)	Terminated	Chronic Myeloid Leukemia	NCT02078960
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients	Terminated	Acute Myeloid Leukemia	NCT02440568
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate	Completed	Hematologic Malignancies\|Solid Tumors	NCT01844869
Azacitidine and Homoharringtonine in JMML	Recruiting	JMML	NCT04505995
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy	Recruiting	Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia	NCT03873311

Showing 1 to 10 of 42 entries

Previous1 2 3 4 5Next

References

Show entries

Search:

Publication	DOI	Pubmed	PMCID
Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. European journal of haematology Hongyan Tong, Yanling Ren, Fengjuan Zhang, Jie Jin, 81, 4, None, 2008-07-08, 10.1111/j.1600-0609.2008.01116.x	10.1111/j.1600-0609.2008.01116.x	18616510	18616510
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Scientific reports Wei Cao, Ying Liu, Ran Zhang, Bo Zhang, Teng Wang, Xianbing Zhu, Lin Mei, Hongbo Chen, Hongling Zhang, Pinghong Ming, Laiqiang Huang, 5, None, 2015-07-13, 2015-07-13, 10.1038/srep08477	10.1038/srep08477	26166037	PMC4499885

Showing 1 to 2 of 2 entries

Vendors

Company	Lnk to product
MERCK/Sigma Aldrich	https://www.sigmaaldrich.com/PL/pl/product/sigma/sml1091

Filter data

Compound	Homoharringtonine
Experiment types	Colony formation assay , Flow cytometry- annexin V binding and propidium iodide staining, Hoechst 33258 assay, MTT, Trypan blue exclusion assay, Tumor volume, Tumor wight , Western Blot
Concentrations	0.12, 0.25, 0.50, 1.00, 10.00, 160.00, 2.00, 20.00, 3.00, 4.00, 40.00, 5.00, 6.00, 60.00, 80.00
Cell lines	A549, H1975, H1975 (xenograft), HEL, HL60, K562, Leukemia patient cells
Organisms	Homo sapiens, Mus musculus
Animal models
STAT proteins	STAT3, STAT5, p-STAT3, p-STAT3 (S727), p-STAT3 (Y705), p-STAT5
Other	AKT1/2/3, Actin, BAX, BCL2, Bcl-xL, Caspase 3, Caspase 9, Cytochrome C, EGFR, ERK1/2, GAPDH, JAK1, JAK2, MCL1, PARP, PDK1, Pim-1, Smad2, Smad3, Survivin, c-Myc, p-AKT1/2/3, p-EGFR, p-ERK1/2, p-JAK1, p-JAK2, p-PDK1, p-Smad2, p-Smad3

Experiments

Show entries

Search:

Compound	Experiment type	Investigated event	Concentration	Cell line	Organism	Animal model	Stat protein	Details
Homoharringtonine	MTT	Influence on cell viability and apoptosis	20.00 ng/ml	HEL	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	20.00 ng/ml	K562	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	20.00 ng/ml	HL60	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	40.00 ng/ml	HEL	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	40.00 ng/ml	K562	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	40.00 ng/ml	HL60	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	80.00 ng/ml	HEL	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	80.00 ng/ml	K562	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	80.00 ng/ml	HL60	Homo sapiens
Homoharringtonine	MTT	Influence on cell viability and apoptosis	160.00 ng/ml	HEL	Homo sapiens

Showing 1 to 10 of 296 entries

Previous1 2 3 4 5…30Next